$BHC

Bausch Health Companies Inc.

Bausch Health is a diversified specialty pharmaceutical and medical device company that develops, manufactures and markets branded, generic and branded generic pharmaceuticals, over-the-counter products, and aesthetic medical devices. Its products address gastroenterology, hepatology, neurology and dermatology, as well as eye health through its approximately 88% ownership of Bausch + Lomb. Products are marketed directly or indirectly in approximately 90 countries. Bausch Health is headquartered in Quebec, Quebec, Canada. The company operates five segments: Salix, which sells U.S. gastrointestinal products; International, which sells branded, branded generic and over-the-counter products outside the U.S., excluding Bausch + Lomb and Solta Medical products; Solta Medical, which sells aesthetic medical devices globally; Diversified, which includes U.S. neurology, dermatology, generic and dentistry products; and Bausch + Lomb, which sells vision care, surgical and pharmaceutical products globally. Bausch Health makes money by selling these products and devices.

AlphAI earnings readthird quarter 2026 · OCT 28Bausch Health Announces Third Quarter 2026 Results, Raises GuidanceVerdict: strong

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

0
0
1

No SEC Form 4 filings for $BHC in the last 30 days.

See all $BHC insider activity →

TSX Climbs to End Week

The TSX gained 183.82 points to close at 35,789.09 on Friday, with gold and materials sectors leading gains. Allied Gold and Lundin Mining rose 6.8% and 5.5% respectively. The Canadian dollar fell 0.54 cents. U.S. markets saw mixed results, with the NASDAQ rebounding 1.1%.

Bausch Health presents data on alcohol-associated hepatitis

Bausch Health (BHC) and Salix Pharmaceuticals presented research on severe alcohol-associated hepatitis at The Liver Meeting 2026. The study found a 62.0% 12-month survival rate, 69.1% rehospitalization rate, and 8.5% liver transplantation rate. The company highlights the unmet medical need in this area.

BHC sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning BHC (Bausch Health Companies Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.

Recent BHC coverage spans financial news, earnings and market movers.

What's driving BHC

AlphAI scores every news story that mentions BHC with an AI model for sentiment and relevance, and aggregates insider trades from Bausch Health Companies Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $BHC

Score

TSX Climbs to End Week

The TSX gained 183.82 points to close at 35,789.09 on Friday, with gold and materials sectors leading gains. Allied Gold and Lundin Mining rose 6.8% and 5.5% respectively. The Canadian dollar fell 0.54 cents. U.S. markets saw mixed results, with the NASDAQ rebounding 1.1%.

Bausch Health, Gibson, Precision Drilling at 52-Week Highs on News

Bausch Health (BHC) reached a 52-week high of $11.89 after reporting Q3 earnings of $1.77 per share, exceeding estimates. Gibson Energy (GEI) hit a 52-week high of $34.08 ahead of its Q3 2026 results release. Precision Drilling (PD) also hit a 52-week high of $151.18, reporting Q3 revenue of $532m and net income of $21m. Power Corporation (POW) and TD Bank (TD) also reached 52-week highs.

Related tickers